Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Neurodermatitis
Interventions
Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Fort Smith, Arkansas • Sacramento, California • Pembroke Pines, Florida + 4 more
Conditions
Prurigo Nodularis, Pruritis
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 33 more
Conditions
Prurigo Nodularis
Interventions
Dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
23
States / cities
Phoenix, Arizona • Fremont, California • Laguna Hills, California + 18 more
Conditions
Prurigo Nodularis
Interventions
CDX-0159, Normal saline
Biological · Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Tempe, Arizona • Miami, Florida • Troy, Michigan + 4 more
Conditions
Prurigo Nodularis
Interventions
barzolvolimab, Matching Placebo
Biological · Other
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 30 more
Conditions
Prurigo Nodularis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
24
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 18 more
Conditions
Prurigo Nodularis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
57
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 49 more
Conditions
Prurigo Nodularis
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Saint Joseph, Missouri
Conditions
Prurigo Nodularis
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Fountain Valley, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Conditions
Prurigo Nodularis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • Arkansas City, Arkansas • Los Angeles, California + 13 more
Conditions
Prurigo Nodularis, Pruritus, Chronic Pruritus, Chronic Prurigo, Skin Diseases
Interventions
Abrocitinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Prurigo Nodularis
Interventions
Upadacitinib
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Windsor, New Jersey
Conditions
Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
Interventions
nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Conditions
Prurigo
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 15 more
Conditions
Prurigo Nodularis
Interventions
INCB054707, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
23
States / cities
Phoenix, Arizona • Fountain Valley, California • Sacramento, California + 19 more
Conditions
Prurigo Nodularis
Interventions
Not listed
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Completed Phase 2Phase 3 Interventional Results available

PRISM Study-Pruritus Relief Through Itch Scratch Modulation

NCT03497975
Conditions
Prurigo Nodularis
Interventions
Nalbuphine ER Tablets, Placebo Tablets
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
36
States / cities
Phoenix, Arizona • Fremont, California • Laguna Niguel, California + 32 more
Not listed Not applicable Interventional

Dapsone Prurigo Study

NCT01870050
Conditions
Lichen Simples Chronicus and Prurigo
Interventions
Dapsone gel - verum
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Prurigo Nodularis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 26 more
Conditions
Pruritus, Prurigo Nodularis
Interventions
5mg Serlopitant Tablets, Placebo Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
49
States / cities
Birmingham, Alabama • Rogers, Arkansas • Fremont, California + 44 more
Conditions
Prurigo Nodularis
Interventions
Nemolizumab 30 mg, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes Following Intralesional Corticosteroid Injections

NCT03630198
Conditions
Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions
Corticosteroid with lidocaine, Corticosteroid with normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Prurigo Nodularis (PN)
Interventions
Lebrikizumab
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
Interventions
5 mg Serlopitant Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more